Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish.

ABSTRACT:

Background

Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments.

Objectives

To identify drug candidates that exhibit synergistic activity with clarithromycin against M. abscessus.

Methods

We performed cell-based phenotypic screening of a compound library against M. abscessus induced to become resistant to clarithromycin. Furthermore, we evaluated the toxicity and efficacy of the top compound in a zebrafish embryo infection m

SUBMITTER: Goh BC 

PROVIDER: S-EPMC10164658 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature